Placebo + RO7017773
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder (ASD)
Conditions
Autism Spectrum Disorder (ASD)
Trial Timeline
Mar 31, 2021 → May 15, 2024
NCT ID
NCT04299464About Placebo + RO7017773
Placebo + RO7017773 is a phase 2 stage product being developed by Roche for Autism Spectrum Disorder (ASD). The current trial status is completed. This product is registered under clinical trial identifier NCT04299464. Target conditions include Autism Spectrum Disorder (ASD).
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder (ASD) were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04299464 | Phase 2 | Completed |
Competing Products
20 competing products in Autism Spectrum Disorder (ASD)